Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RCUS
RCUS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RCUS News
Wall Street Analysts Adjust Ratings
3d ago
Benzinga
Arcus Biosciences Grants Stock Options to Employees
Jan 26 2026
Businesswire
Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
Jan 07 2026
Newsfilter
Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million
Jan 06 2026
Fool
Arcus Biosciences Insider Sells 82,997 Shares for $2.1 Million Amid Market Highs
Jan 06 2026
NASDAQ.COM
Arcus Overhauls Cancer Development Strategy After Trial Setback, Focuses on Kidney Medication
Dec 12 2025
Benzinga
Significant Options Trading on Friday: SEI, CAVA, RCUS
Dec 12 2025
NASDAQ.COM
Wedbush Raises Arcus Biosciences Price Target to $37, Up from $35, While Keeping Outperform Rating
Dec 12 2025
Yahoo Finance
Arcus Biosciences and Gilead Halt Phase 3 STAR-221 Cancer Study Due to Lack of Efficacy
Dec 12 2025
NASDAQ.COM
Gilead and Arcus suspend advanced trial for anti-TIGIT cancer treatment
Dec 12 2025
SeekingAlpha
Arcus Biosciences Grants New Employee 3,600 Stock Options at $25.80 Each
Dec 09 2025
Newsfilter
B of A Securities Upholds Neutral Rating for Arcus Biosciences (RCUS)
Nov 29 2025
NASDAQ.COM
B of A Securities Keeps Neutral Rating on Arcus Biosciences and Increases Price Target to $26
Nov 28 2025
Benzinga
Semtech Reports Mixed Q3 Results, Alongside Zhihu, Nvidia, and Other Major Stocks Declining in Tuesday's Pre-Market Trading
Nov 25 2025
Benzinga
Keysight Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 25 2025
Benzinga
The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip
Nov 23 2025
Benzinga
Show More News
